Home/Pipeline/REC-617

REC-617

Advanced Solid Tumors

Phase 1/2Active

Key Facts

Indication

Advanced Solid Tumors

Phase

Phase 1/2

Status

Active

Company

Recursion Pharmaceuticals

About Recursion Pharmaceuticals

Recursion Pharmaceuticals is pioneering a TechBio approach to industrialize drug discovery, leveraging its proprietary Recursion OS—a closed-loop platform integrating automated wet labs, one of the world's largest fit-for-purpose biological datasets (>50 PB), and machine learning foundation models. The company has built a maturing clinical pipeline, with its lead asset, REC-4881 for Familial Adenomatous Polyposis (FAP), in Phase 2 and multiple other oncology programs in Phase 1/2. Its strategy centers on scaling its platform to systematically discover and develop first-in-class and best-in-class medicines, supported by strategic partnerships with pharmaceutical and technology leaders.

View full company profile

Therapeutic Areas

Oncology Rare Disease

Other Advanced Solid Tumors Drugs

Drug	Company	Phase	Status
NT219	Purple Biotech	Phase 1/2	Active
INDP-101	Indaptus Therapeutics	Phase 1	Active, not recruiting
NST-101 (estimated)	Novastage Pharmaceuticals	Phase 1/2	Active
Meta10-TILs	Leman Biotech	Phase 1	Active (Investigator-Initiated Trial)
PM14	PharmaMar	Phase 1/2	Active
Ecubectedin (PM54)	PharmaMar	Phase 1	Active
M8891	Merck KGaA	Phase 1/2	Active
P-002	Panacea Biotec	Phase 1/2	Active
Undisclosed kinase inhibitor	Tyligand Bioscience	Phase 1	Active
TYK-001	TYK Medicines	Phase 1/2	Active
PT-112	SciClone Pharmaceuticals	Phase 1	Active - Subject Recruitment
AP-202	Advance Pharmaceutical	Phase 1/2	Active, dose expansion